AIM ImmunoTech (AIM) announced that Paul Goepfert, MD, of the University of Alabama-Birmingham, has agreed to act as the Principal Investigator ...
As global capital reassesses the investment value of innovative Chinese companies, the development of innovative vaccines in ...
Paul Goepfert, MD, Director for the Alabama Vaccine Research Clinic, stated: "I'm excited for the opportunity to follow-up on ...
Innovation and Global Expansion Attract Capital Reassessment AIM Vaccine Co., Ltd. (a joint stock company incorporated in the People's Republic of China with limited liability) (Stock Code: 6660.HK) ...
An update from AIM Vaccine Co., Ltd. Class H ( ($HK:6660) ) is now available. AIM Vaccine Co., Ltd. announced the strategic integration of ...
AIM ImmunoTech Inc. announced plans to advance its drug Ampligen as a vaccine adjuvant for avian influenza, marking a new initiative in its antiviral development pipeline. The company has ...
As recently analyzed in a research report by FOSUN International Securities, “For investors looking to enter the vaccine industry, AIM Vaccine integrates innovative technology, industry leadership, ...
The executive order on Friday largely took aim at mandates implemented in 2021, shortly after Covid vaccines became available. Some local school districts, especially in more liberal regions ...
As global capital flows positively into the pharmaceutical sector, PRC vaccine leader AIM Vaccine (06660.HK) announced on February 26 that its self-developed mRNA RSV (Respiratory Syncytial Virus) ...